Palisade Bio (PALI) Share-based Compensation Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.79% |
| Dec 31, 2025 | 51.26% |
| Sep 30, 2025 | -33.71% |
| Jun 30, 2025 | -31.33% |
| Mar 31, 2025 | -5.56% |
| Dec 31, 2024 | -41.56% |
| Sep 30, 2024 | -20.77% |
| Jun 30, 2024 | -0.59% |
| Mar 31, 2024 | -29.95% |
| Dec 31, 2023 | 56.86% |
| Sep 30, 2023 | 7.35% |
| Jun 30, 2023 | -6.05% |
| Mar 31, 2023 | -17.19% |
| Dec 31, 2022 | -20.20% |
| Sep 30, 2022 | -5.24% |
| Jun 30, 2022 | -12.42% |
| Mar 31, 2022 | -7.28% |
| Dec 31, 2021 | 3.37% |
| Sep 30, 2021 | -29.20% |
| Jun 30, 2021 | -9.54% |
| Mar 31, 2021 | -17.30% |
| Dec 31, 2020 | -10.76% |
| Sep 30, 2020 | -3.78% |
| Jun 30, 2020 | -8.89% |
| Mar 31, 2020 | -35.69% |
| Dec 31, 2019 | -29.40% |
| Sep 30, 2019 | -14.82% |
| Jun 30, 2019 | -24.95% |
| Mar 31, 2019 | -32.66% |
| Dec 31, 2018 | -23.94% |
| Sep 30, 2018 | -33.13% |
| Jun 30, 2018 | -19.90% |
| Mar 31, 2018 | -12.91% |
| Dec 31, 2017 | -8.88% |
| Sep 30, 2017 | -7.49% |
| Jun 30, 2017 | 14.54% |
| Mar 31, 2017 | 7.13% |
| Dec 31, 2016 | 4.77% |
| Sep 30, 2016 | -2.81% |
| Jun 30, 2016 | -5.04% |
| Mar 31, 2016 | 5.07% |
| Dec 31, 2015 | -8.55% |
| Sep 30, 2015 | -9.30% |